Navigation Links
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Date:8/22/2007

SOMERSET, N.J., Aug. 22 /PRNewswire-FirstCall/ - Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in the International Journal of Oncology (2007; Vol. 31, Issue 3: 663-669) reports that ONCONASE(R) substantially decreases reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer agents.

The pre-clinical in vitro research conducted by Alfacell and researchers at New York Medical College demonstrated that treatment of cells in cultures with ONCONASE reduced intracellular oxidative stress by suppressing ROI generation and promoting their degradation. The anti-oxidative function of ONCONASE may be an important element of its antiproliferative/cytotoxic activity towards cancer cells and a possible mechanism of its well-documented synergism with other anti-cancer agents. Additionally, the data indicate that ONCONASE has a propensity to reverse the generation of ROI from asbestos exposure in mesothelial cells. The Company is currently conducting a Phase IIIb human clinical trial of ONCONASE for the treatment of patients suffering from unresectable malignant mesothelioma.

"The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "ONCONASE's therapeutic potential is broad. This study shows that ONCONASE has potential not only for cancer, but for conditions pathogenetically related to oxidative stress or the activation of NF-kappa B, such as inflammation, autoimmune diseases, atherosclerosis and septic shock."

About ONCONASE(R)
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... Aug. 1, 2011 Biodel Inc. (Nasdaq: BIOD ... results on August 4, 2011.  Following the release of the ... call to discuss the results and provide an update on ... fiscal year 2011 results will be distributed4:15 pm EDT: , ...
... 2011 Reportlinker.com announces that a new ... catalogue: Insulin- Global ... This package contains 63 insulin market analyses ... Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, ...
Cached Medicine Technology:Insulin- Global 2
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... country's greenest and cleanest city was not enough, Chandigarh is all ... become the first smoke-free city in the country. ... free by July 1. ,The joint capital of Punjab ... and buildings to ensure that smoking is restricted and the general ...
... a million less AIDS patients than has been widely believed, ... were reported here. ,The survey that was ... out under international supervision shows that India probably no longer ... the New York Times said Friday. ,An official ...
... epilepsy in developing countries are being denied an effective ... according to an editorial in this weeks BMJ. ... in developing countries to ensure that effective treatment is ... people with epilepsy who live in developing countries, around ...
... (hESC), those very young cells that are a biological blank ... to the workings of a wide variety of organs and ... slow to be realized because of the ongoing ethical debate ... its a politically charged issue in the U.S. because it ...
... of tumors and the response of tumors to radiation ... in turn limits oxygen delivery to the tumor, causing ... shown to trigger tumor resistance to radiation via the ... known as HIF-1regulated cytokines. In a study appearing online ...
... community hospita,l in Detroit with 285 beds, specializing in general ... failure, diabetes and obstetrics. ,Detroit is the largest ... a prosperous region. ,But Riverview is all ... week said it was losing too much money and already ...
Cached Medicine News:Health News:Chandigarh to Become India's First Smoke-free City 2Health News:India Has a Million Less AIDS Cases Than Believed: Study 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 3
... As the leader in liquid handling, ... Finnpipette Novus, a pipette that combines simplicity, ... ergonomic design. Built on the results of ... the new Finnpipette Novus gives you the ...
... The StaRRsed-III is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
... complete range of automatic systems for performing ... mL of blood. With the introduction of ... clinical diagnostic market a truly revolutionary testing ... limitation associated with the traditional ESR techique.,By ...
... The NEW VACUETTE erythrocyte sedimentation ... can help. The new generation unites ... analysers with whole range of additional ... of the erythrocyte sedimentation rate. Cost ...
Medicine Products: